<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818725</url>
  </required_header>
  <id_info>
    <org_study_id>GETUG-AFU 19/0903</org_study_id>
    <nct_id>NCT02818725</nct_id>
  </id_info>
  <brief_title>I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations</brief_title>
  <acronym>GETUG-AFU19</acronym>
  <official_title>Intensified Methotrexate, Vinblastine, Doxorubicin and Cisplatin +/-Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma in Patients Without Harvey Nor Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations. Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES OF THE TRIAL

      Primary objective

      Evaluation of efficacy in terms of progression-free survival at 9 months of the combination
      of intensified methotrexate, vinblastine, doxorubicin and cisplatin with or without
      panitumumab as first-line treatment of advanced urothelial carcinoma in patients without
      Harvey nor Kirsten rat sarcoma viral oncogene homolog mutations.

      Secondary objectives

        -  To assess toxicity

        -  To assess response rate

        -  To assess overall survival

        -  To assess time to progression

        -  To study the correlation between response rate, time to progression, overall survival
           and biological parameters
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>9 months</time_frame>
    <description>Progression-Free Survival at 9 months post-treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicities assessment</measure>
    <time_frame>24 months</time_frame>
    <description>toxicity (CTC AE v4.0) after end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of response</measure>
    <time_frame>24 months</time_frame>
    <description>Recist 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of time to progression</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Infiltrating Urothelial Carcinoma</condition>
  <condition>KRAS Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intensified- Methotrexate Vinblastin Doxorubicin Cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: chemotherapy + panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensified- Methotrexate Vinblastin Doxorubicin Cisplatin +/- panitumumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>METHOTREXATE 30 mg/m2 on day 1 VINBLASTINE 3 mg/m2 on day 2 DOXORUBICIN 30 mg/m2 on day 2 CISPLATIN 70 mg/m2 on day 2</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>Arm B: chemotherapy + panitumumab</arm_group_label>
    <other_name>Intensified-Methotrexate Vinblastine Doxorubicin Cisplatin</other_name>
    <other_name>I-MVAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>panitumumab</intervention_name>
    <description>PANITUMUMAB 6 mg/kg on day 2</description>
    <arm_group_label>Arm B: chemotherapy + panitumumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Primary tumour of the bladder or upper urinary tract

          2. Histologically confirmed infiltrating urothelial carcinoma (epidermoid and/or
             glandular forms are accepted)

          3. Patients without Harvey and Kirsten-rat sarcoma viral oncogene homolog mutations

          4. Advanced disease defined by a locally advanced stage (T4 and/or N+) ineligible for
             surgical resection, or a metastatic stage (M1)

          5. Patients with at least 1 evaluable lesion as per RECIST criteria (version 1.1)

          6. 18 ≤ age ≤ 75 years

          7. General condition 0 or 1 as per the WHO scale

          8. Absence of previous chemotherapy for advanced disease (chemotherapy with gemcitabine
             and platinum salt delivered as an adjuvant is accepted if this ended more than a year
             ago)

          9. Haematological function: Haemoglobin &gt; 11 g/dl, neutrophils ≥ 1500/mm3, platelets ≥
             100,000/mm3

         10. Liver function: Grade* 0 Aspartate aminotransferase and Alanine aminotransferase (&lt;
             grade* 3 for liver metastases), grade* 0 alkaline phosphatases, normal bilirubin

         11. Renal function: calculated (or measured) creatinine clearance &gt; 60 ml/min

         12. Patients covered by a social security scheme

         13. Patient having read the information sheet and signed the informed consent form.

        Exclusion Criteria:

          1. Pure adenocarcinoma or pure epidermoid carcinoma or mixed or pure small-cell
             neuroendocrine carcinoma

          2. Previous treatment with one of the following molecules: methotrexate, vinblastine,
             doxorubicin or Epidermal Growth Factor inhibitor

          3. History of interstitial pneumonitis or pulmonary fibrosis

          4. History of cardiovascular disease (including myocardial infarction, unstable angina,
             symptomatic congestive heart failure, uncontrolled serious cardiac arrhythmia) in the
             year prior to randomisation (≤ 1 year)

          5. Ventricular ejection fraction &lt; 50%

          6. Blood calcium and/or magnesium ≥ grade* 1

          7. History of cancer in the 5 years prior to entry in the trial other than basal cell
             skin cancer or in situ epithelioma of the cervix,

          8. Treatment with radiotherapy for analgesic purposes (unless treatment was discontinued
             at least 15 days prior to inclusion in the trial)

          9. Potential allergy to panitumumab

         10. Male or female patients not agreeing to use an effective method of contraception
             throughout the duration of treatment and for 6 months after treatment discontinuation

         11. Pregnant women, or female subjects liable to become pregnant or currently
             breast-feeding,

         12. Patient already included in another therapeutic trial on an investigational medicinal
             product,

         13. Persons deprived of their freedom or under judicial protection (including
             guardianship),

         14. Unable to receive medical follow-up during the trial owing to geographical, social or
             psychological reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Nimes</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diaconesses - Croix St Simon</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Cancerologie de La Loire</name>
      <address>
        <city>St Priest En Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2011</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

